Form 4: AnaptysBio Executive Acquires 20,000 Shares Through Performance Stock Units

Eric Loumeau, Chief Legal Officer of AnaptysBio, Inc., acquired 20,000 shares of common stock on July 22, 2024, through the vesting of performance stock units.

Summary

• On July 22, 2024, Eric Loumeau, the Chief Legal Officer of AnaptysBio, Inc., acquired 20,000 shares of the company's common stock.
• The acquisition was a result of the vesting of performance stock units (PSUs).
• Each PSU represents a contingent right to receive one share of AnaptysBio's common stock upon the achievement of certain share price metrics.
• 50% of the shares subject to the PSU that achieve the applicable performance metrics will vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026.
• An additional 50% of the shares will vest on the 2-year anniversary of such achievement, but not later than July 1, 2028, subject to the Reporting Person' service to the Issue on each vesting date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects the achievement of performance metrics, leading to the vesting of shares. However, future vesting is still contingent on further performance and continued service.

Positives

• The vesting of performance stock units suggests that the company may have achieved certain share price metrics, which is a positive indicator.
• The structure of the PSU vesting, tied to both performance metrics and continued service, incentivizes the executive to remain with the company and contribute to its success.

Risks

• The vesting of the remaining PSU shares is contingent on continued service and the achievement of further performance metrics, which introduces uncertainty.

Future Outlook

The future vesting of the remaining PSU shares is dependent on the achievement of further share price metrics and the continued service of the reporting person.

Industry Context

Executive compensation in the biotech industry often includes performance-based equity awards like PSUs to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded biotechnology companies.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based incentive plans for their executives.
• The specific performance metrics and vesting schedules vary depending on the company's strategic goals and industry benchmarks.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign, indicating that the company is achieving its performance goals.
• Employees may be motivated by the potential for similar performance-based compensation.

Key Dates